JP Morgan Call 165 ABT 16.01.2026/ DE000JK50Z98 /
2024-08-02 8:50:06 AM | Chg.+0.050 | Bid12:35:29 PM | Ask12:35:29 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.160EUR | +45.45% | 0.160 Bid Size: 15,000 |
0.230 Ask Size: 15,000 |
Abbott Laboratories | 165.00 USD | 2026-01-16 | Call |
GlobeNewswire
06-06
Circana’s 2023 New Product Pacesetters Report Reveals Innovation Is Meeting Consumers in New Moments
GlobeNewswire
05-09
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new Pre...
GlobeNewswire
03-25
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
GlobeNewswire
03-15
Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt B...
GlobeNewswire
2023-11-14
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports In...
GlobeNewswire
2023-10-19
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
GlobeNewswire
2023-10-10
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
GlobeNewswire
2023-10-02
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
GlobeNewswire
2023-09-06
Endexx Corporation Appoints Ahmed Itani to Director of Marketing of HYLA in The Middle East Region